Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Takeda seeks Japanese approval for brentuximab vedotin to treat relapsed/refractory CD30 positive HL and ALCL
Takeda seeks Japanese approval for brentuximab vedotin to treat relapsed/refractory CD30 positive HL and ALCL
Takeda seeks Japanese approval for brentuximab vedotin to treat relapsed/refractory CD30 positive HL and ALCL
Submitted by
admin
on March 23, 2013 - 10:15am
Source:
Pharmabiz
News Tags:
Takeda
brentuximab vedotin
systemic anaplastic large cell lymphoma
Headline:
Takeda seeks Japanese approval for brentuximab vedotin to treat relapsed/refractory CD30 positive HL and ALCL
Do Not Allow Advertisers to Use My Personal information
